Close

News

Malvern, Purdue collaborate to advance nanotechnology

Malvern Instruments and Birck Nanotechnology Center at Purdue University have enterted into collaboration to examine the application of light scattering techniques in the characterization of nanoparticles and advance nanotechnology. The collaboration is formed for...

Harmonix introduces non-prescription sleep aid

Harmonix has introduced Sleep Formula 39 to overcome sleep problems and to provide a better night's sleep. Sleep Formula 39 is a non-prescription sleep aid made up with a proprietary combination of sleep ingredients...

CellCura partners IDT Biologika for protein free media

CellCura has entered into a memorandum of understanding  with IDT Biologika  to test and adapt its patented protein free media used in the production of human vaccine. The protein free media improves safety and stability in...

USP opens new testing facility in India

US Pharmacopeial Convention  has opened a new expanded testing facility in the IKP Knowledge Park in Hyderabad, India. The new facility will allow voluntary testing and auditing program that helps dietary supplement manufacturers ensure and attest...

BioVigilant submits rapid biologic detection systems DMFs with FDA

BioVigilant has submitted Type V drug master files of IMD-A 300 series of rapid biologic detection systems to the US Federal Drug Administration.BioVigilant's IMD system is used to detect the presence of bacteria in the pharmaceutical manufacturing environments. ...

Mannatech adds vitamin D to omega-3 supplement

Mannatech, a developer and provider of nutritional supplements and skin care products based on Real Food Technology solutions, has added vitamin D to its omega-3 supplement. The new Omega-3 with Vitamin D3 capsules now comprise 830...

Isconova, Genocea widen licensing deal

Isconova and Genocea Biosciences have widened their existing agreement, under which Isconova has given license for using its Matrix M to Genocea Biosciences in vaccines targeting two additional diseases. Currently, Genocea has the right to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read